Novartis AG (NVS) announced FDA approval for Lutathera (lutetium Lu 177 dotatate) for pediatric patients aged 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Lutathera is the first therapy specifically approved for pediatric GEP-NET patients, offering a significant advancement in their treatment options.
Results for: Lutathera
The U.S. Food and Drug Administration (FDA) has approved Novartis’ Lutathera for children 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This marks the first approval of a medicine for children with this type of rare cancer.